ILC Therapeutics Announces Board Changes and Funding Round to Accelerate Covid-19 Drug ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a new class of interferon drugs, announces the strengthening of its Board and Management as well as a pre-IPO funding round to advance its lead novel hybrid interferon drug candidate Alfacyte. The appointments announced are Peter Bains as Non-Executive Chairman, Richard Morgan as a Non-Executive Director and Allan Watson as Chief Financial Officer. Dr Magnus Nicholson, Chairman of ILC Therapeutics, will become senior adviser and non-executive director on the board. These appointments will significantly strengthen ILC therapeutics' Board and executive team as the company seeks to accelerate plans to advance its novel technology platform and prepare its lead candidate, Alfacyte, for clinical trials.